San­doz joins up with B2B phar­ma to com­mer­cial­ize six biosim­i­lars in the US

No­var­tis sub­sidiary San­doz has joined up with B2B phar­ma Adal­vo in a dis­tri­b­u­tion and col­lab­o­ra­tion agree­ment for six un­named biosim­i­lar prod­ucts in the US, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.